staff members with anti-HBs antibodies to care these patients, special measures to prevent the contamination of the patients' blood and biological fluids, adequate disinfection of the material used, and the vaccination of patients and staff if necessary [8] . Currently, there is no routine method to detect HTLV-III [9] . We can only use the test for anti-HTLV-III antibodies by Elisa [10] , but this method does not show in any particular time that the patients are virus carriers, but only suggests that they have had contact with the virus. Furthermore, seronegative carriers [11] and false-positive and false-negative cases [12] pose another problem. However, while there is no method to detect HTLV-III, it is imperative to test for HTLV-III antibodies in every potential high-risk patient on hemodialysis. If the forecasts made about the future extent of AIDS are correct [1] , this test must be included in every hemodialysis candidate as a part of the preliminary examination. The patients with positive HBs antigen are dialyzed in separate units. The isolation of patients with anti-376 Robles/López-Gomez/Muiño/Altozano/Valderrabano HTLV-III antibodies seems to be essential. However, at least in the present situation, the low number of these patients does not permit the creation of separate units, and, therefore, an, alternative treatment may be continuous ambulatory peritoneal dialysis. Nevertheless, the future creation of special units for these patients is a frightening possibility to bear in mind. Another risk to consider is the contamination from health workers, and although at the present time it does not appear necessary to screen the staff members, this possibility must be considered for the future. At present, there is no vaccine available against AIDS [8] , but the appearance of such a vaccine would be welcomed, particularly if we consider the concern that the care of these patients produces among nursing and auxiliary workers. Finally, we must point out that all special measures to prevent the contamination with AIDS patients' blood or body fluids and to disinfect the used materials are particularly emphasized. In summary, until we have no sensitive and specific methods to diagnose AIDS, as well as the chance to vaccinate hemodialysis patients and staff members, these isolated hemodialysis units for AIDS patients and HTLV-III carriers will not be realized, and, therefore, continuous ambulatory peritoneal dialysis may be an alternative treatment, taking the necessary measures to advise the nurse responsible for training about the subsequent risks. References Fauci, S.: The acquired immunodeficiency syndrome. An update. Ann. intern. Med. 102:800-813 (1985) . Nephrol. 27:197-204 (1984) .
